TITLE

Treatment of Aggressive Non-Hodgkin's Lymphoma with Chemotherapy in Combination with Filgrastim

AUTHOR(S)
Schriber, J.
PUB. DATE
June 2002
SOURCE
Drugs;2002 Supplement 1, Vol. 62 Issue 9, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Non-Hodgkin's lymphoma (NHL) is one of the ten most common cancers in the developed world. The incidence has increased significantly over the past two decades and it is a particular burden in patients over the age of 60 years. The gold standard for primary treatment of aggressive NHL is combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Haematological growth factors, such as granulocyte colony-stimulating factor (G-CSF), can be used to ameliorate chemotherapy-induced neutropenia, thus facilitating delivery of chemotherapy at the planned dose intensity. The International Prognostic Index is able to identify high-risk patients who are unlikely to be cured with standard primary chemotherapy. In these patients, the use of dose-intensive therapy, including high-dose chemotherapy with stem cell support, is being evaluated as potential primary therapy. Stem cell transplantation is currently the treatment of choice for patients with relapsed NHL or those with chemosensitive refractory disease. Autologous peripheral blood stem cells mobilised into the circulation by G-CSF help achieve rapid haematological reconstitution and are now the preferred source of stem cells over bone marrow for this form of therapy. G-CSF is also used to support allogeneic transplantation, which exerts a therapeutic graft-versus-lymphoma effect. Administration of G-CSF following autologous or allogeneic peripheral blood stem cell transplantation accelerates neutrophil recovery.
ACCESSION #
7732517

 

Related Articles

  • Focused trials needed to reduce chemo toxicities in older HL patients.  // Reactions Weekly;4/1/2013, Issue 1446, p1 

    An abstract of the article "ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials," by B. Böll and colleagues is presented.

  • BEACOPP escalated may be new standard of care for advanced-stage Hodgkin's lymphoma.  // Hem/Onc Today;9/25/2013, Vol. 14 Issue 18, p32 

    The article discusses a study by N. Skoetz and colleagues which found that initial therapy with six cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) escalated extended survival in patients with advanced-stage Hodgskin's lymphoma.

  • Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens. Ahmadzadeh, Ahmad; Saeed Yekaninejad, Mir; Jalili, Mohamad H.; Bahadoram, Mohammad; Efazat, Mehdi; Seghatoleslami, Mohammad; Yazdi, Fatemeh; Mahdipour, Mozhdeh; Valizadeh, Armita; Saki, Najmaldin // International Journal of Hematology-Oncology & Stem Cell Researc;Apr2014, Vol. 8 Issue 2, p21 

    In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with...

  • Radioimmunotherapy of lymphoma. Goldsmith, Stanley J. // Archive of Oncology;2013, Vol. 21 Issue 2, p136 

    Radiolabeled monoclonal antibodies for the treatment of follicular low-grade non-Hodgkin's lymphoma have been available for several years in the United States and more recently throughout Europe. Since their introduction to treatment of refractory or relapsed patients, they have been evaluated...

  • Peripheral T Cell Non-Hodgkin’s Lymphoma following Treatment of Hodgkin’s Lymphoma. Chang, Sun Hee; Lee, Hye Ran // Case Reports in Oncological Medicine;1/13/2015, Vol. 2015, p1 

    Previous reports have suggested that non-Hodgkin’s lymphoma (NHL) is more likely to develop in patients with Hodgkin lymphoma (HL) compared to the general population. These two can occur synchronously or metachronously. We report here on a case of nodular sclerosis classical HL and T cell...

  • De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkin's lymphoma. Seignez, Antoine; Casasnovas, Olivier; Ferrant, Emmanuelle; Bastie, Jean; Mondoloni, Pauline; Aho, Ludwig; Boulin, Mathieu; Bastie, Jean Noel; Aho, Ludwig Serge // International Journal of Clinical Pharmacy;Dec2015, Vol. 37 Issue 6, p1033 

    Background: There is a need to develop treatment strategies that are less toxic than BEACOPPescalated x6 cycles, the standard-of-care in advanced Hodgkin's lymphoma patients.Objective: To compare short-term hematological toxicity in advanced Hodgkin's lymphoma patients...

  • Combined Therapy More Effective for Early-Stage Hodgkin Lymphoma. McBride, Deborah // ONS Connect;May2011, Vol. 26 Issue 5, p6 

    The article reports that the patients who were treated with a combined therapy of radiation and chemotherapy for the early-stage Hodgkin lymphoma lived longer than patients who received chemotherapy alone, according to a study by C. Herbst and colleagues.

  • Cancer Chemotherapy Update. Solimando Jr., Dominic A.; Waddell, Aubrey // Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p858 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and...

  • Therapy-Related Late Adverse Events in Hodgkin's Lymphoma. Gotti, Manuel; Fiaccadori, Valeria; Bono, Elisa; Landini, Benedetta; Varettoni, Marzia; Arcaini, Luca; Bonfichi, Maurizio // Lymphoma (2090309X);2013, p1 

    Hodgkin's lymphoma (HL) is one of themost curable hematologic diseases with an overall response rate over 80%.However, despite this therapeutic efficacy,HLsurvivors showa highermorbidity andmortality than other people of the sameage because of long-term therapy-related events. In the last...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics